Keryx Biopharmaceuticals, Inc. (KERX) Receives Consensus Rating of “Hold” from Brokerages

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has received a consensus rating of “Hold” from the nine research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $7.00.

Several equities analysts have recently issued reports on KERX shares. Cowen and Company reiterated a “market perform” rating on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. BidaskClub downgraded Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Morgan Stanley reiterated an “equal weight” rating and set a $7.00 price objective (up from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Maxim Group set a $9.00 target price on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. Finally, ValuEngine upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st.

Keryx Biopharmaceuticals (NASDAQ KERX) traded down $0.08 during trading hours on Monday, hitting $4.79. The stock had a trading volume of 1,476,303 shares, compared to its average volume of 1,519,802. Keryx Biopharmaceuticals has a 52 week low of $4.47 and a 52 week high of $8.38. The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.03). The company had revenue of $15.00 million for the quarter, compared to the consensus estimate of $18.88 million. Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The firm’s revenue for the quarter was up 138.1% compared to the same quarter last year. During the same period last year, the company posted ($0.39) earnings per share. equities research analysts anticipate that Keryx Biopharmaceuticals will post -1.36 EPS for the current year.

Large investors have recently made changes to their positions in the business. Westpac Banking Corp acquired a new position in shares of Keryx Biopharmaceuticals in the second quarter worth $390,000. TIAA CREF Investment Management LLC increased its stake in shares of Keryx Biopharmaceuticals by 3.6% in the second quarter. TIAA CREF Investment Management LLC now owns 220,336 shares of the biopharmaceutical company’s stock worth $1,593,000 after acquiring an additional 7,576 shares during the last quarter. Gotham Asset Management LLC acquired a new position in shares of Keryx Biopharmaceuticals in the second quarter worth $402,000. Schwab Charles Investment Management Inc. increased its stake in shares of Keryx Biopharmaceuticals by 1.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 441,106 shares of the biopharmaceutical company’s stock worth $3,190,000 after acquiring an additional 4,388 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Keryx Biopharmaceuticals by 39.2% in the second quarter. Alliancebernstein L.P. now owns 191,650 shares of the biopharmaceutical company’s stock worth $1,386,000 after acquiring an additional 54,010 shares during the last quarter. 65.44% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/18/keryx-biopharmaceuticals-inc-kerx-receives-consensus-rating-of-hold-from-brokerages.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

What are top analysts saying about Keryx Biopharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Keryx Biopharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit